A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data
2020; American Association for Cancer Research; Volume: 29; Issue: 9 Linguagem: Inglês
10.1158/1055-9965.epi-19-1527
ISSN1538-7755
AutoresMinh‐Phuong Huynh‐Le, Chun Fan, Roshan Karunamuni, Eleanor Walsh, Emma L. Turner, J. Athene Lane, Richard M. Martin, David E. Neal, Jenny Donovan, Freddie C. Hamdy, J. Kellogg Parsons, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, Kenneth Muir, Henrik Grönberg, Fredrik Wiklund, Markus Aly, Johanna Schleutker, Csilla Sipeky, Teuvo L.J. Tammela, Børge G. Nordestgaard, Timothy J. Key, Ruth C. Travis, Paul D.P. Pharoah, Nora Pashayan, Kay‐Tee Khaw, Stephen N. Thibodeau, Shannon K. McDonnell, Daniel J. Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S. Kibel, Cezary Cybulski, Dominika Wokołorczyk, Wojciech Kluźniak, Lisa Cannon‐Albright, Hermann Brenner, Ben Schöttker, Bernd Holleczek, Jong Y. Park, Thomas A. Sellers, Hui‐Yi Lin, Chavdar Kroumov Slavov, Radka Kaneva, Vanio Mitev, Jyotsna Batra, Judith A. Clements, Amanda B. Spurdle, Manuel R. Teixeira, Paula Paulo, Sofia Maia, Hardev Pandha, Agnieszka Michael, Ian G. Mills, Ole A. Andreassen, Anders M. Dale, Tyler M. Seibert,
Tópico(s)Colorectal Cancer Screening and Detection
ResumoA polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.
Referência(s)